# Impact of Endogenous E2 on SSI and GH Rebound

> **NCT02026973** · PHASE1 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 62 (actual)

## Conditions studied

- Normal Healthy Volunteers

## Interventions

- **DRUG:** Fulvestrant
- **DRUG:** Anastrozole
- **DRUG:** Placebo
- **DRUG:** Somatostatin

## Key facts

- **NCT ID:** NCT02026973
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2015-11
- **Final completion:** 2015-11
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2016-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02026973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02026973, "Impact of Endogenous E2 on SSI and GH Rebound". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02026973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*